Archive for the ‘bioengineering’ category: Page 16

Jul 5, 2023

Robot skin heals

Posted by in categories: bioengineering, biotech/medical, cyborgs, robotics/AI

Robotic finger. Illustration showing the cutting and healing process of the robotic finger (A), its anchoring structure (B) and fabrication process ©. ©2022 Takeuchi et al.

Researchers from the University of Tokyo pool knowledge of robotics and tissue culturing to create a controllable robotic finger covered with living skin tissue. The robotic digit has living cells and supporting organic material grown on top of it for ideal shaping and strength. As the skin is soft and can even heal itself, the finger could be useful in applications that require a gentle touch but also robustness. The team aims to add other kinds of cells into future iterations, giving devices the ability to sense as we do.

Professor Shoji Takeuchi is a pioneer in the field of biohybrid robots, the intersection of robotics and bioengineering. Together with researchers from around the University of Tokyo, he explores things such as artificial muscles, synthetic odor receptors, lab-grown meat, and more. His most recent creation is both inspired by and aims to aid medical research on skin damage such as deep wounds and burns, as well as help advance manufacturing.

Jul 4, 2023

AI combined with CRISPR precisely controls gene expression

Posted by in categories: bioengineering, biotech/medical, robotics/AI

Artificial intelligence can predict on-and off-target activity of CRISPR tools that target RNA instead of DNA, according to new research published in Nature Biotechnology.

The study by researchers at New York University, Columbia University, and the New York Genome Center, combines a with CRISPR screens to control the expression of human in different ways—such as flicking a light switch to shut them off completely or by using a dimmer knob to partially turn down their activity. These precise gene controls could be used to develop new CRISPR-based therapies.

CRISPR is a gene editing technology with many uses in biomedicine and beyond, from treating sickle cell anemia to engineering tastier mustard greens. It often works by targeting DNA using an enzyme called Cas9. In recent years, scientists discovered another type of CRISPR that instead targets RNA using an enzyme called Cas13.

Jun 30, 2023

Dr. Brad Ringeisen, Ph.D. — Executive Director, Innovative Genomics Institute (IGI)

Posted by in categories: bioengineering, biotech/medical, chemistry, food, genetics, governance, health, neuroscience

Is the Executive Director of the Innovative Genomics Institute (, an organization founded by Nobel Prize winner Dr. Jennifer Doudna, on the University of California, Berkeley campus, whose mission is to bridge revolutionary gene editing tool development to affordable and accessible solutions in human health and climate.

Dr. Ringeisen is a physical chemist with a Ph.D. from the University of Wisconsin-Madison, a Bachelor of Science in chemistry from Wake Forest University, a pioneer in the field of live cell printing, and an experienced administrator of scientific research and product development.

Continue reading “Dr. Brad Ringeisen, Ph.D. — Executive Director, Innovative Genomics Institute (IGI)” »

Jun 28, 2023

David Zuniga, Senior Director, In-Space Solutions, Axiom Space — Developing Low Earth Orbit Economy

Posted by in categories: bioengineering, business, economics, government, policy, space

Developing The Low Earth Orbit Economy On The World’s First Commercial Space Station — David Zuniga, Senior Director, In-Space Solutions, Axiom Space

David Zuniga is Senior Director of In-Space Solutions at Axiom Space (, a space infrastructure developer headquartered in Houston, Texas, which plans human spaceflight for government-funded and commercial astronauts, engaging in in-space research, in-space manufacturing, and space exploration. The company aims to own and operate the world’s first commercial space station, and Mr. Zuniga helps to develop strategy and growth around Axiom’s Low Earth Orbit (LEO) economy, also playing a critical role in business and technical integration of Axiom’s in-space manufacturing and research capabilities for Axiom Station architecture.

Continue reading “David Zuniga, Senior Director, In-Space Solutions, Axiom Space — Developing Low Earth Orbit Economy” »

Jun 18, 2023

Fabrication of Nanofiltration Membranes via Surface and Interface Engineering

Posted by in categories: bioengineering, chemistry, sustainability

A team of researchers successfully constructed nanofiltration membranes with superior quality using the mussel-inspired deposition methods. Such was achieved via a two-part approach to fabricate the thin-film composite (TFC) nanofiltration membranes. Firstly, the substrate surface was coated through fast and novel deposition to form a dense, robust, and functional selective layer. Then, the structure controllability of the selective layer was enhanced by optimizing the interfacial polymerization (IP) process. As a result, the properties of nanofiltration membranes produced are with high durability and added functionality. When put into a bigger perspective, these high-performance TFC nanofiltration membranes are potential solutions to a number of fields, including water softening, wastewater treatment, and pharmaceutical purification. Hence, there is a need to further explore and expand the application in an industrial scale instead of being bound within the walls of the laboratories.

Membrane-based technologies, especially enhanced nanofiltration systems, have been highly explored due to their myriad of distinct properties, primarily for their high efficiency, mild operation, and strong adaptability. Among these, the TFC nanofiltration membranes are favoured for their smaller molecular weight cutoff, and narrower pore size distribution which lead to higher divalent and multivalent ion rejection ability. Moreover, these membranes show better designability owing to their thin selective layer make-up and porous support with different chemical compositions. However, the interfacial polymerization (IP) rate of reaction is known to affect the permeability and selectivity of the TFC nanofiltration membranes by weakening the controllability of the selective layer structure. Therefore, this study was designed to improve the structural quality of the TFC nanofiltration membranes through surface and interface engineering, and subsequently, increase the functionality.

Continue reading “Fabrication of Nanofiltration Membranes via Surface and Interface Engineering” »

Jun 17, 2023


Posted by in categories: bioengineering, cosmology, education, governance, quantum physics, robotics/AI, space travel

A sci fi documentary exploring a timelapse of future space colonization. Travel through 300 years, from 2052 to 2,301 and beyond, and see how modern science fiction becomes reality.

Witness the journey of humans expanding from Earth, to the Moon, to Mars, and beyond.

Continue reading “TIMELAPSE OF SPACE COLONIZATION (2052 — 2301+)” »

Jun 11, 2023

Researchers advance DNA nanostructure stability

Posted by in categories: bioengineering, biotech/medical, computing, genetics, nanotechnology

Researchers at the University at Albany’s RNA Institute have demonstrated a new approach to DNA nanostructure assembly that does not require magnesium. The method improves the biostability of the structures, making them more useful and reliable in a range of applications. The work appears in the journal Small this month.

When we think of DNA, the first association that comes to mind is likely genetics—the within cells that houses an organism’s blueprint for growth and reproduction. A rapidly evolving area of DNA research is that of DNA nanostructures—synthetic molecules made up of the same as the DNA found in living cells, which are being engineered to solve critical challenges in applications ranging from medical diagnostics and delivery to materials science and data storage.

“In this work, we assembled DNA nanostructures without using magnesium, which is typically used in this process but comes with challenges that ultimately reduce the utility of the nanostructures that are produced,” said Arun Richard Chandrasekaran, corresponding author of the study and senior research scientist at the RNA Institute.

Jun 10, 2023

Synthetic Life

Posted by in categories: bioengineering, genetics, robotics/AI

Sign up for a Curiosity Stream subscription and also get a free Nebula subscription (the streaming platform built by creators) here:
We often discuss cybernetic, genetic engineering, artificial intelligence, and hybrids of them, but what truly is synthetic life? And what is it like?

Visit our Website:
Support us on Patreon:
Facebook Group:
Twitter: on Twitter and RT our future content.
SFIA Discord Server:

Continue reading “Synthetic Life” »

Jun 10, 2023

Team develops magnetic microrobots with folate to promote targeted drug delivery to cancer cells

Posted by in categories: bioengineering, biotech/medical, cyborgs, transhumanism

The limited ability of microrobots to assist drugs in entering cells hinders their therapeutic efficacy. To address this, a research team, reporting in Cyborg and Bionic Systems, has introduced the cancer-targeting molecule folic acid (FA) to microrobots to promote drug uptake by cancer cells via receptor-ligand-mediated endocytosis. This results in a drug delivery system that can locate lesion areas with magnetic fields and deliver loaded drugs into the cytoplasm through endocytosis.

Untethered microrobots have shown remarkable achievements in various fields such as minimally invasive surgery, , environmental remediation, and tissue engineering. Magnetic field actuation is a widely used method due to its good biosafety, deeper tissue penetration, and high temporal and spatial control.

However, practical problems arise when microrobots delivering drugs may only be able to deliver the drugs to the area around the cells but cannot assist the drugs to enter the cells. This limitation could potentially reduce the effectiveness of the treatment since the drugs may not reach the intended targets within the cells.

Jun 10, 2023

Reversing Multiple Sclerosis Symptoms Using Immune Cells

Posted by in categories: bioengineering, biotech/medical, neuroscience

Multiple sclerosis (MS) affects roughly 2.5 million people worldwide and is a neurological disease affecting the brain and spinal cord. More specifically, MS is when the immune system attacks the body’s protective layer around nerve fibers known as myelin sheaths. The breakdown of myelin sheath leads to a disconnect between your brain and body. The immune cells responsible for myelin sheath deterioration include CD4+ T cells, or effector cells, which are part of the body’s first line of defense. In MS, the effector cells do not recognize that the myelin sheath is a normal part of the body. Therefore, the effector cells become the dominant cell type, trying to kill and get rid of the myelin sheath. The immune response will generate inflammation which destroys the myelin sheath leading to a disruption of signals along the nerves from the brain to the body.

A group of researchers at Johns Hopkins University School of Medicine recently published a therapy that controls the symptoms of MS. The goal of the therapy was to stop effector cells from attacking the myelin sheath and to promote the production of T regulatory cells-or T regs-which have been demonstrated to reduce autoimmune effects.

Dr. Giorgio Raimondi, PhD, MSc, Jordan Green, and others used three therapeutic agents to control MS symptoms. Researchers used microparticles, which are small, bioengineered spheres to deliver the agents. The first agent is a combination of two proteins which include Interleukin-2 (IL2) and an antibody that promotes T reg production. IL2 stimulates T cell expansion, while the antibody blocks specific parts of IL2 to specifically expand T regs compared to effector cells. The second agent includes a molecule that presents a protein specific to myelin so that the immune response will generate T regs specifically designed to protect the myelin sheath. Finally, the third agent is rapamycin, which is an immunosuppressant drug designed to reduce effector T cells.

Page 16 of 196First1314151617181920Last